Published in Respir Med Case Rep on November 19, 2015
Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med (1999) 8.96
Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med (2006) 4.20
Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) (2007) 2.90
Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol (2010) 2.53
Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J (2008) 1.99
Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol (2008) 1.88
The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest (2008) 1.78
A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) (2008) 1.35
A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis (2008) 1.33
A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum (2007) 1.31
The renaissance of corticotropin therapy in proteinuric nephropathies. Nat Rev Nephrol (2011) 1.28
Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis (2000) 1.21
Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther (2012) 1.12
Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J (2013) 1.10
Alveolar macrophages are the main source for tumour necrosis factor-alpha in patients with sarcoidosis. Eur Respir J (2003) 1.04
Prolonged use of methotrexate for sarcoidosis. Arch Intern Med (1995) 1.03
Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol (2010) 1.02
Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler (2012) 0.99
Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Clin Rheumatol (2000) 0.91
Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford) (2003) 0.90
Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus (2014) 0.86
Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2014) 0.85
A retrospective pilot study examining the use of Acthar gel in sarcoidosis patients. Respir Med (2015) 0.83
Chronic facial sarcoidosis including lupus pernio: clinical description and proposed scoring systems. Am J Clin Dermatol (2008) 0.83
Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. JAMA Dermatol (2013) 0.83
A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept. Clin Rheumatol (2011) 0.80
Effect of Acthar-c (ACTH) in sarcoidosis. Ann Intern Med (1952) 0.78
Effect of cortisone in sarcoidosis. Trans Stud Coll Physicians Phila (1951) 0.77
Oral ACTH (H.P. Acthar(®)Gel) inhibits IL-1 and IL-17 secretion in humans. Biomed Pharmacother (2011) 0.77